BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 9, 2004
View Archived Issues
Opportunistic Axonyx Raises $50M Through Public Market
Months after raising $25 million in a private placement, Axonyx Inc. is at it again. But this time, Axonyx has set its sights higher, looking to bring in $50 million. (BioWorld Today)
Read More
Novacea Series C Gets $35M To Push Cancer Compounds
Read More
Myogen Begins Enrollment For Ambrisentan Phase III Studies
Read More
Esperion Gets $32.2M From Settlement With Stockholder
Read More
Keryx Acquiring Three Phase II Drugs In 'Success-Based' Buyout
Read More
With 'Hybrid' Business Model, Infinity Signs Amgen To Deal
Read More
ImmunoGen Moving Forward Alone With Cancer Products
Read More
Other News To Note
Read More